Lv3
316 积分 2023-12-05 加入
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
1个月前
已完结
[Evaluation considerations for using surrogate endpoints in anticancer clinical trials]
1个月前
已完结
SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant
2个月前
已完结
Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review
2个月前
已完结
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
2个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
4个月前
已完结
Navigating the Evolving Landscape of EGFR -Mutated NSCLC
4个月前
已完结
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
7个月前
已完结
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
8个月前
已完结
皖公网安备34019202002308
